Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840148 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
A Phase 3 study of Urinary Tract Infections and Acute Pyelonephritis, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 661
- Enrollment target
- 20
- Study locations
NCT03840148 is a Phase 3 study of Urinary Tract Infections and Acute Pyelonephritis that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 661 participants, above the 439-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT03840148, a Phase 3 study of Urinary Tract Infections and Acute Pyelonephritis, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 661 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
Conditions Studied
Interventions
- DRUG Meropenem
- DRUG Cefepime/VNRX-5133 (taniborbactam)
Study Locations (20)
Other
- Site 103203 - Córdoba
- Site 107601 - Belo Horizonte
- Site 107608 - São Paulo
- Site 110009 - Gabrovo
- Site 110002 - Pleven
- Site 110007 - Plovdiv
- Site 110003 - Rousse
- Site 110010 - Sofia
- Site 110004 - Sofia
- Site 110005 - Sofia
- Site 110008 - Sofia
- Site 110001 - Veliko Tarnovo
- Site 156022 - Baotou
- Site 156002 - Beijing
- Site 156006 - Beijing
- Site 156015 - Chendu
California
- Site 184003 - Buena Park
- Site 184002 - Chula Vista
- Site 184001 - La Mesa
- 184012 - Northridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840148
The ClinicalTrials.gov registry entry for NCT03840148 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 439-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (51% higher). The listed sponsor is Venatorx Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which Meropenem is the first listed.
NCT03840148 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT03840148 about?
NCT03840148 is a clinical study titled "Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections". This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
What is the current status of trial NCT03840148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2019-08-07. Estimated completion is 2021-12-14.
What conditions does trial NCT03840148 study?
This clinical trial studies the following conditions: Urinary Tract Infections, Acute Pyelonephritis.
What interventions are being tested in trial NCT03840148?
The interventions under investigation include: Meropenem (DRUG), Cefepime/VNRX-5133 (taniborbactam) (DRUG).
Who is sponsoring clinical trial NCT03840148?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03840148 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
COMPLETED · Phase 3
-
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
COMPLETED · Phase 3
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.